PD-1 inhibitors for urothelial cancer: combination or sequential therapy?
暂无分享，去创建一个
[1] M. Galsky,et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial , 2020, The Lancet.
[2] M. Galsky,et al. Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Culine,et al. Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.